The hepatitis B treatment market is a vital component of the pharmaceutical industry, addressing the global challenge of Hepatitis B virus (HBV) infection. Market dynamics in this sector are shaped by factors such as the prevalence of HBV, advancements in antiviral therapies, and efforts to improve access to treatment.
The heavy worldwide disease burden of hepatitis B infection affects market dynamics. The high incidence of HBV in certain areas and populations contributes to the demand for quality treatment options, playing a role in determining how competitive this market is due to pharmaceutical companies trying so hard to address such public health issues.
Significant changes in market dynamics are associated with the steady development of antiviral therapy for hepatitis B as it has been innovated by nucleoside and nucleotide analogs, immune modulator therapies together with combination.
Massive establishment of hepatitis B immunization programs impacts market dynamics. The successful effort of vaccination helps to decrease new infections and this reflects on the market because it makes people focus more on treatment for those who are already affected, while indicating that complete health care solutions should be provided.
The contribution of enhanced hepatitis B screening and diagnosis to market dynamics is the identification of more individuals with this condition. As awareness generation programs increase, patients become aware that they can contract Hepatitis b; hence, demand for antiviral treatments increases further driving market trends due to increased need time intervention.
Connections between chronic HBV infection and the onset of liver cirrhosisand hepatocellular carcinoma drive market dynamics. Healthcare policies as well as preferences of the patients are affected by an emphasis on preventing severe complications through antiviral treatments.
Different regions market dynamics differ based on the state of healthcare infrastructure. Mature healthcare systems facilitate the accessibility of hepatitis B treatments, contributing to market trend changes by ensuring broad use and distribution of antiviral products.
Global dimension of the pharmaceutical industry affects market dynamics. Hecatilis B markets are divided across regions, and firms position themselves strategically to meet the market needs in terms of differences in heath care infrastructure, regulatory environments as well as patient demographics.
The government initiatives and funding for hepatitis B treatment programs directly affect market dynamics. The efforts from public health agencies and financing into research in turn help to create new treatments, dictating the general market structure.
The market dynamics influenced by the patient advocacy groups and educational initiatives on hepatitis B are that patients become informed, which leads to seeking treatment thereby influencing trends in markets as individuals actively participate in their health management.
The hepatitis b treatment market is expected to reach USD 129.40 Billion by 2032 at 4.5% CAGR during the forecast period 2023-2032.
The viral infection is caused by Hepatitis A, B or C virus which causes liver infection leading to liver damage. Hepatitis B virus can transmit in contact with infected blood, by consumption of contaminated water, and by using infected needles. Some of the major symptoms are weakness, jaundice, poor appetite, dark-coloured urine, skin itching, leg swelling, weight loss, drowsiness and others. The rise in concern for a better treatment for Hepatitis B is boosting the market at the global level.
The availability of hepatitis B treatment and the awareness of hepatitis B infections will significantly drive the market in the forecast period. The concern and reasonable treatment are the two growth factors that highly accelerate the market’s growth. The advancement in the development of new treatments and medications with a higher success rate will lead the market towards greater opportunities. The continuous development of drugs and vaccines for hepatitis B treatment is aiding the market. AIDS survivors with haemodialysis and immunosuppressants are propelling the market’s growth in the forecast period
The hepatitis B treatment market is segmented on the basis of type, treatment, distribution channel, and region.
Based on type, the market is segmented into acute and chronic. On the basis of treatment, the hepatitis B treatment market is segmented into immune modulator drugs, antiviral drugs, vaccine, and surgery (liver transplant). The immune modulator drugs are further sub-segmented into pegylated interferon and interferon alpha. The antiviral drugs are sub-segmented into tenofovir disoproxil, entecavir, telbivudine, lamivudine, and others. By distribution channel, the market is segmented into hospital & retail pharmacies and online pharmacies.
Based on region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
Some of the key players in the hepatitis B treatment market are Accord Healthcare Inc., Apotex Corp., Arbutus Biopharma, Arrowhead Pharma, Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Par Pharmaceutical, Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals, and Others.
Global Hepatitis B Treatment Market Share (%), by Region, 2017
Sources: Centers for Disease Control and Prevention, GOV.UK, Society of Cardiovascular Computed Tomography, Indian Brand Equity Foundation, Annual Reports, Press Release, White Paper, And Company Presentation
The Americas dominates the global market for hepatitis B treatment owing to the increasing bacterial infection, development in the clinical practices, and availability and access of best treatments for viral infection in this region.
Moreover, high healthcare expenditure within the Americas boosts the regional market. According to the National Vaccine Information Center, there were 3,370 acute cases of hepatitis B in the US in 2015. Following similar trends, Europe stood second in the global hepatitis B treatment market. On a regional basis, the European market is segmented into Western Europe and Eastern Europe. Europe is estimated to lead the market due to the presence of advanced medical facilities and rising viral infection among the population contributes to increasing the new cases of hepatitis B among the population. According to the World Health Organization data sheet, hepatitis B and C affects a large number of people in the European region. It also, stats that globally, 1.5 million people die every year because of hepatitis B virus. The increasing incidences of hepatitis B in Europe boost market growth.
Asia Pacific is estimated to be the fastest growing region for the hepatitis B treatment market in 2017. A rapidly growing medical diagnostic sector, growing prevalence of bacterial infection and a large number of patients suffering from HIV infection support market growth.
In April 2022
Gilead Sciences, Inc. has declared that U.S. Food and Drug Administration (FDA) approved its new drug application (sNDA) for Veklury (remdesivir) for pediatric patients treatment older than 28 days, weighing 3 kg. Patients with COVID-19 or moderate COVID-19 are considered at high risk for progression hospitalization or death. This approval for sNDA follows Veklury non-hospitalized adult and adolescent patients treated at high risk of severe COVID-19.
In April 2022
Antios Therapeutics, Inc, a global clinical-stage biopharmaceutical company that has developed advanced therapies for the treatment of chronic hepatitis B virus. It has recently been announced that the United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application Phosphoramidates for Hepatitis B Virus treatment. The compositions contain Antios' novel Active Site Polymerase Inhibitor Nucleotide), ATI-2173, along with other therapies and mechanisms.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)